Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome.
- Author:
Jae Min KIM
1
;
Jae Hui KIM
;
Young Suk CHANG
;
Jong Woo KIM
;
Chul Gu KIM
;
Dong Won LEE
Author Information
- Publication Type:Original Article
- Keywords: Bevacizumab; Choroidal neovascularization; Macular degeneration; Ranibizumab; Retinal angiomatous proliferation
- MeSH: Bevacizumab; Choroidal Neovascularization; Diagnosis; Endothelial Growth Factors*; Humans; Macular Degeneration; Observational Study; Ranibizumab; Retinaldehyde*; Retrospective Studies; Tomography, Optical Coherence; Visual Acuity
- From:Korean Journal of Ophthalmology 2017;31(3):240-248
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To evaluate the 12-month outcome of intravitreal anti-vascular endothelial growth factor therapy in eyes with bilateral retinal angiomatous proliferation (RAP). METHODS: This retrospective observational study included 38 eyes of 19 patients with stage 1 or 2 bilateral RAP at diagnosis. The eyes of patients who exhibited different baseline best-corrected visual acuity (BCVA) values in both eyes were assigned to one of two groups—the better (n=13) and worse (n=13) visual acuity groups. The BCVA values in both groups were compared to those at baseline and at 12 months. In addition, the 12-month changes in BCVA were compared between the two groups. The association between the optical coherence tomography findings at diagnosis and the 12-month BCVA was also analyzed. RESULTS: The values of mean baseline and 12-month BCVA in the better visual acuity group (13 eyes) were 0.48 ± 0.19 and 0.58 ± 0.29, respectively, and those in the worse visual acuity group (13 eyes) were 0.83 ± 0.20 and 0.90 ± 0.31. The 12-month changes in BCVA were not significantly different between the two groups (p=0.786). Among the six patients with equivalent baseline BCVA in both eyes, four patients (66.7%) exhibited 1 to 2 lines or ≥3 lines of difference in BCVA between eyes at 12 months. Eyes without pigment epithelial detachment (PED) at diagnosis exhibited significantly better BCVA at 12 months than eyes with PED (p=0.021). CONCLUSIONS: Better baseline visual acuity was associated with better BCVA at 12 months posttreatment in patients with bilateral RAP. However, equivalent baseline visual acuity in both eyes might not guarantee similar treatment outcomes. In addition, the absence of PED is predictive of better visual outcome.
